Sanofi Patient Connection

Connecting Patients to Medication and Resources

Access and Reimbursement


Provides certain Sanofi prescription medications at no cost to patients who meet program eligibility requirements

Learn about eligibility
Financial Assistance


Supports patients and providers in determining insurance coverage and options. Services include benefit verification, prior authorization or appeals assistance, and alternative coverage research

Learn more
Resource Support


Helps identify additional resources and support for program patients and caregivers as appropriate

Find support
Sanofi Patient Connection

To learn more about Sanofi Patient Connection

Dosing and Administration

Learn about the process of administering Mozobil.

access dosing schedule

About Mozobil

In clinical trials, Mozobil + granulocyte-colony stimulating factor (G-CSF) was shown to significantly reduce mobilization failures. Learn more about the clinical trials.1-3

see study results

Abbreviations: G-CSF, granulocyte-colony stimulating factor.


  1. Mozobil [prescribing information]. Cambridge, MA: Genzyme Corporation; 2020.
  2. DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin’s lymphoma. J Clin Oncol. 2009;27(28):4767-4773.
  3. DiPersio JF, Stadtmauer EA, Nademanee A, et al; for the 3102 Investigators. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113(23):5720-5726.